top signin

Pin It

interior-banner-mask

.

Press 2018

Nov 08, 2018

Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Director...

HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


Nov 08, 2018

Biostage Reports 2018 Third Quarter Financial Results...

 - Scientific feedback along with new and consistent data continue to validate technology - Ongoing studies support mid-year 2019 filing of IND   HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- ...


Nov 07, 2018

Ms. Ting Li Appointed to Biostage Board of Directors...

HOLLISTON, Mass., Nov. 7, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


Nov 06, 2018

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cell...

- These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate   HOLLISTON, Mass., Nov. 6­­­, 2018 /PRNewswire/ -- Biostage, Inc....


Nov 02, 2018

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results...

- Conference Call with Live Audio Webcast on Thursday November 8th at 9:30 AM ET -   HOLLISTON, Mass., Nov. 2, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing...


Aug 14, 2018

Biostage Reports 2018 Second Quarter Financial Results...

- Company making steady progress on mid-term goals - On-track with execution strategy including filing IND in 2019   HOLLISTON, Mass., Aug. 14, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG)...


Aug 09, 2018

Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Result...

- Conference Call with Live Audio Webcast on Tuesday, August 14th at 9:00 AM ET -   HOLLISTON, Mass., Aug. 9, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing...


May 31, 2018

Biostage Closes $3.6 Million Private Placement at a price of $3.60 per share...

HOLLISTON, Mass., May 31, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


May 31, 2018

Hong Yu Appointed President of Biostage...

HOLLISTON, Mass., May 31, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


May 25, 2018

Dr. Wei Zhang Elected to Biostage's Board of Directors...

HOLLISTON, Mass., May 25, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


May 10, 2018

Biostage Reports 2018 First Quarter Financial Results...

  - Steady progress in the new year signals strengthening financial and technology positions   HOLLISTON, Mass., May 10, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company...


May 04, 2018

Biostage to Host Conference Call to Discuss First Quarter 2018 Financial Results...

- Conference Call with Live Audio Webcast on Thursday, May 10th at 9:00 AM ET -   HOLLISTON, Mass., May 4, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing...


Apr 02, 2018

Biostage Reports 2017 Financial Results...

- Fourth Quarter Headcount Reduction and Private Placement Extend Operational Runway   HOLLISTON, Mass., April 2, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a...


Mar 29, 2018

Biostage Names Distinguished Children's Hospital Executive James Shmerling to it...

HOLLISTON, Mass., March 29, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the...


Mar 29, 2018

Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant...

- Potential to provide up to $1.7 million of nondilutive funds to support pre-clinical testing of Company's pediatric esophageal implant product candidate   HOLLISTON, Mass., March 29, 2018 /...


Mar 13, 2018

Biostage Preclinical Study Results Published in New Report...

Large-animal study results published in Nature Scientific Reports show successful esophageal regeneration   HOLLISTON, Mass., March 13, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a...


Feb 20, 2018

Biostage Closes $1 Million Private Placement...

HOLLISTON, Mass., Feb. 20, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and...


Feb 20, 2018

Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD...

HOLLISTON, Mass., Feb. 20, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and...


Feb 12, 2018

Biostage Appoints to its Scientific Advisory Board Charles S. Cox, Jr., MD...

HOLLISTON, Mass., Feb. 12, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea,...


Feb 12, 2018

Biostage, Inc. Names Jason Chen Chairman of its Board of Directors...

HOLLISTON, Mass., Feb. 7, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus,...


Feb 06, 2018

Biostage to Host Conference Call to Provide Business Update...

- Conference Call with Live Audio Webcast on Tuesday, February 13th at 9:00 AM ET -   HOLLISTON, Mass., Feb. 6, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing...


Jan 31, 2018

Biostage Appoints to its Scientific Advisory Board Christine Finck, MD, Executiv...

HOLLISTON, Mass., Jan. 31, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus,...


Jan 03, 2018

Biostage Closes $4.2 Million Private Placement...

- Investors strongly back technology, advancement to the clinic in U.S. Market- - Company plans to establish a presence in China to address the largest incidence of esophageal cancer worldwide- -...